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Abstract
Background: Previous data from our institution showed that hypofractionated thoracic radiotherapy (HypoTRT)
with concurrent etoposide/platinum chemotherapy yielded favorable survival in patients with limited-stage small
cell lung cancer (LS-SCLC). The present study retrospectively compared the survival outcomes, failure patterns and
toxicities between groups of LS-SCLC patients treated with conventionally fractionated thoracic radiotherapy
(ConvTRT) or HypoTRT combined with chemotherapy.
Methods: Medical records of LS-SCLC patients between January 2010 and December 2013 at Fudan University
Shanghai Cancer Center were retrospectively reviewed. All patients treated with chemotherapy and ConvTRT
(2 Gy per fraction daily, DT ≥ 56 Gy) or HypoTRT (2.5 Gy per fraction daily, DT = 55 Gy) were eligible for analysis.
Progression-free survival (PFS) and overall survival (OS) were generated for different populations using the Kaplan-
Meier method and compared using the log-rank test. Comparisons of failure patterns and toxicity were analyzed
using the χ2 test.
Results: A total of 170 patients treated with HypoTRT (n = 69) or ConvTRT (n = 101) were eligible for analysis.
The median PFS and OS were 13.7 and 25.3 months, respectively, in the ConvTRT cohort, which was similar to
the HypoTRT cohort (PFS 18.2 months, p = 0.991, and OS 27.2 months, p = 0.698), with a median follow-up of
30 months. Multivariate analysis revealed that PCI and TNM stage were prognostic factors for PFS and that PCI was
prognostic for OS. The patterns of failure (stratified by local-regional recurrence, distant metastasis or both as first
relapse) were similar between the dose cohorts (p = 0.693, p = 0.330, p = 0.572). Distant metastasis remained the
main failure pattern. The brain was the most frequent remote failure site, followed by bone, liver and adrenal gland.
PCI improved the 2-year survival rate from 46.1% to 70.0% and the 2-year PFS rate from 20.9% to 45.3%,
respectively (p < 0.001). Grade ≥3 esophagitis and pneumonitis occurred in 9.9% and 11.9%, respectively, of the
patients in the ConvTRT cohort and in 11.6% and 10.0%, respectively, of those in the HypoTRT cohort (p = 0.815).
Conclusion: This retrospective analysis demonstrated that HypoTRT or ConvTRT combined with etoposide/platinum
chemotherapy yielded statistically similar survival, treatment failure outcomes, and toxicity profiles. PCI correlated
with improved PFS and OS.
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Background
Lung cancer remains the leading cause of cancer-related
deaths worldwide [1]. Small-cell lung cancer (SCLC)
accounts for almost 13% of all new cases, and it is distin-
guished from non-small-cell lung cancer (NSCLC) by a
more rapid doubling time, higher growth fraction and
early metastatic dissemination [2]. Limited stage small
cell lung cancer (LS-SCLC) is diagnosed in approxi-
mately one-third of patients, and it is potentially curable.
The combined-modality treatment of chemotherapy and
thoracic radiotherapy (TRT), particularly concurrent
chemoradiotherapy (CRT) for those with good perform-
ance status, followed by prophylactic cranial irradiation
(PCI) is the standard of care for LS-SCLC [3]. The
addition of TRT to systemic chemotherapy improves
long-term survival and local control [4, 5]. Nearly 20%
of the LS-SCLC patients who received concurrent CRT
achieved 5-year survival with a median overall survival
(OS) of 19.9 months [6].
A current consensus of the optimal TRT dose fraction
regimen is lacking. The hallmark INT0096 study favored
twice-daily 45 Gy in 3 weeks (1.5 Gy per fraction) with
concurrent cisplatin/etoposide chemotherapy, which sig-
nificantly improved the OS compared to once-daily 45 Gy
in 5 weeks (1.8 Gy per fraction) [7]. Hyperfractionated-
accelerated radiotherapy became one of the recommended
standard TRT regimens. However, this study was continu-
ously debatable for the low biological equivalent dose
(BED) in the once-daily group and the high rate of grade 3
or worse esophagitis in the twice-daily group. The Cancer
and Leukemia Group B (CALGB) conducted a series of
studies in which conventionally fractionated thoracic
radiotherapy (ConvTRT) with high dose of 70 Gy was
applied concurrently with chemotherapy to achieve im-
provements in survival and local control with tolerable
radiation-associated toxicities [6, 8–11]. The phase III
study (CONVERT) compared concurrent twice-daily CRT
(45 Gy/30 F) with once-daily CRT (66 Gy/33 F) in patients
with LS-SCLC and showed similar survival outcomes
and toxicities, with the exception of significantly more
grade 3/4 neutropenia in the twice-daily arm. The
CONVERT results supported the use of either once-
daily or twice-daily RT as the standard of care for pa-
tients with LS-SCLC [12].
Nevertheless, twice-daily RT was not widely adopted
because of toxicity and inconvenience. Once-daily RT
remained the most commonly used regimen for LS-
SCLC. Once-daily HypoTRT with a shortening of the
overall treatment time may optimize survival and tumor
control [13]. Murray et al. [14] reported a favorable effi-
cacy of HypoTRT (40 Gy/15 F) early in 1993, during the
era of two-dimensional radiotherapy, with a median OS
and 5-year survival rate of 21.2 months and 22%, re-
spectively. An ensuing phase II study of HypoTRT
55 Gy (2.5 Gy per fraction) and concurrent chemother-
apy achieved a median OS of 28.5 months and a 2-year
survival rate of 58.2% [15]. LS-SCLC patients in our
institution were treated with once-daily TRT (either
ConvTRT or HypoTRT) combined with chemotherapy.
Few studies have compared the ConvTRT and HypoTRT.
The present study retrospectively compared the survival
outcomes, failure patterns and toxicities between ConvTRT
and HypoTRT in combination with etoposide/platinum




A database of patients with histologically or cytologically
proven SCLC at Fudan University Shanghai Cancer
Center between January 2010 and December 2013 was
retrospectively reviewed. Routine staging evaluation of
SCLC consisted of a medical history and physical exam-
ination, CBC and comprehensive chemistry panel with
renal and hepatic function tests, contrast-enhanced chest
CT scans, contrast-enhanced abdomen CT scans or ab-
domen ultrasound, bone scan, and MRI or CT scan of
the brain. Whole-body PET-CT was not mandatory. The
initial staging of LS-SCLC was based on the Veterans
Administration Lung Study Group (VALSG) two-stage
classification and a modified staging system proposed by
the International Association for the Study of Lung
Cancer (IASLC) [16]. Except for contralateral hilar
lymph node involvement and ipsilateral pleural effu-
sions, patients with contralateral mediastinal or bilateral
supraclavicular lymph node metastases were eligible for
analysis.
Treatment delivery
Patients were immobilized in the supine position with a
thermoplastic head and shoulder mask or on a vacuum
pad with arms placed over the head. A simulation CT
with slice thickness of 5 mm was performed. CT images
were imported to a treatment planning system to create
a treatment design. All patients received induction
chemotherapy. The gross tumor volume (GTV) contour-
ing of primary tumor in lung, mediastinal lymph nodes
and involved lymph nodal regions were based on pre-
treatment chest CT and/or PET scan, and restage chest
CT. The clinical target volume (CTV) was not outlined
in these patients. The planning target volume (PTV) was
generated with a margin of 1.0-1.5 cm added to GTV.
All patients were treated using the 3D-CRT or IMRT
technique. The volume of PTV that received less than
95% of the prescription dose should not exceed 1%, and
the volume of PTV that received less than 99% of the
prescription dose should not exceed 5%. The dose toler-
ance of organs at risk was constrained. The following
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parameters were used for the HypoTRT cohort:
maximum spinal cord dose ≤42 Gy; V20 (percentage of
lung volume receiving > 20 Gy) ≤ 25%; mean lung dose
≤14.5 Gy; and mean heart dose ≤27 Gy. The following
parameters were used for the ConvTRT cohort: max-
imum spinal cord dose ≤45 Gy; V20 (percentage of lung
volume receiving > 20 Gy) ≤ 30%; mean lung dose
≤15 Gy; and mean heart dose ≤30 Gy.
The chemotherapy regimens were EP or EC. The EP
regimen consisted of cisplatin (25 mg/m2/days 1–3) and
etoposide (100 mg/m2/days 1–3). The EC regimen con-
sisted of carboplatin (AUC 5-6/day 1) and etoposide
(100 mg/m2/days 1–3). Chemotherapy was administered
every 3–4 weeks for four to six cycles, and the doses
were modified according to the toxicity grade by the
treating physicians. Tumor response was assessed using
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0. Toxicity was assessed using Common
Terminology Criteria Adverse Events (CTCAE) version
3.0 of the National Cancer Institute (NCI). All patients
underwent CBC, comprehensive chemistry panel with
renal and hepatic function tests, and CT of the chest
with intravenous contrast at 1 month after the comple-
tion of therapy. Patients who achieved partial or
complete tumor response in the chest were considered
for PCI. The follow-up times were typically 3 months for
the first year and 6 months for the next 2 years. Chest
CT and abdomen CT or ultrasound examination were
routinely performed during follow-up. Brain MRI or CT
and bone scan were performed when symptoms were
reported.
Statistical analysis
The Statistical Package for Social Sciences (SPSS version
20.0, IBM, USA) software was used for statistical analyses.
Comparisons of categorical variables were performed
using Fisher’s exact test or the χ2 test. Independent-
samples T test was used for continuous measures to assess
the differences between the groups. The Kaplan-Meier
method was used to estimate overall survival (OS),
progression-free survival (PFS), time to locoregional re-
currence, and distant metastasis. OS was defined as time
from the initiation of treatment to death. PFS was defined
as time from the initiation of treatment to disease progres-
sion or death. Time to locoregional recurrence was de-
fined as time from the initiation of treatment until the
date of locoregional failure as a first event. Time to distant
metastasis was similarly defined. Log-rank tests were used
to evaluate differences in the time-to-event outcomes
between the groups with two-sided p values. Statistical
significance was defined as a p-value less than 0.05. We
used the Cox regression model to detect whether associ-
ated clinical factors were predictors for OS and PFS.
Results
Patient characteristics
A total of 170 patients treated with ConvTRT (2 Gy per
fraction daily, median 60 Gy/30 F, range from 56 Gy/
28 F to 66 Gy/33 F) or HypoTRT (2.5 Gy per fraction
daily, DT = 55 Gy) combined with etoposide/platinum
chemotherapy were eligible for analysis. Nine patients
who received a hyperfractionated regimen were excluded
from the analysis. Sixty-nine of the 170 patients received
HypoTRT, and 101 patients received ConvTRT. Table 1
summarizes the baseline characteristics of the patients.
Patient- and treatment-related variables were compara-
tive between the two cohorts, except for PCI and CRT
modality. Sixty-three patients (91.3%) received concur-
rent CRT in the HypoTRT group and 53 patients started
early concurrent HypoTRT with the 1st to 3rd cycle of
chemotherapy. Fifty patients (49.5%) were treated with






















Concurrent CRT 63(91.3%) 50(49.5%)
Early radiotherapy 53 34
Late radiotherapy 10 16
Sequential CRT 6(8.7%) 51(50.5%)
Cycles of chemotherapy 0.924
<4 cycles 12(17.4%) 17(16.8%)




Abbreviations: PCI prophylactic cranial irradiation
CRT chemoradiotherapy
ECOG Eastern Cooperative Oncology Group
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concurrent CRT in the ConvTRT group and 34 patients
received early concurrent ConvTRT (p < 0.001). PCI
(25 Gy/10 F) was administered to 66.7% and 47.5% of
the patients with partial or complete response in
chest tumors in the HypoTRT and ConvTRT cohorts
(p = 0.014), respectively.
Response evaluation
Patients were assessed using chest CT scans according
to the RECIST version 1.0 after the completion of CRT.
The overall objective response rate was 97%, with
complete and partial response achieved in 32% and 65%
of the patients, respectively, and 2 patients (3%) achieved
stable disease in the HypoTRT group. Twenty-eight
patients in the ConvTRT group exhibited complete re-
sponse (28%), 69 patients exhibited partial response
(68%), and 4 patients exhibited stable disease (4%).
There was no significant difference in the response rate
between the groups (p = 0.806).
Survival
The last follow-up date was November 2016. Nine
patients were lost to follow-up. The median follow-up
time was 30 months, with a range from 4 to 82 months.
Of the 170 patients, 120 (70.6%) patients suffered treat-
ment failure: 52 in the HypoTRT group and 68 in the
ConvTRT group. The median PFS was 17.0 months
(95%CI: 14.0–20.0) for the entire group of patients. The
median PFS was 18.2 months (95% CI: 15.8–20.6) and
13.7 months (95% CI: 11.3–16.1) for the HypoTRT and
ConvTRT cohorts, respectively (p = 0.991). The 1-year
and 2-year PFS rates were 64.8% and 32.4%, respectively,
for patients who received HypoTRT compared to 61.6%
and 33.5%, respectively, for patients who received
ConvTRT (Fig. 1a).
One hundred and nineteen of the 170 patients (70%)
died: 49 patients in the HypoTRT group and 70 patients
in the ConvTRT group. The median OS was 26.8 months
(95% CI: 24.9–28.7) for all patients, 27.2 months (95% CI:
25.2–29.2) for patients who received HypoTRT, and
25.3 months (95% CI: 22.5–28.1) for patients who received
ConvTRT (p = 0.698). The 1- and 2-year survival rates
were 87.0% and 62.2%, respectively, for patients in the
HypoTRTgroup compared with 82.2% and 57.3%, respect-
ively, of the patients treated with ConvTRT (Fig. 1b).
Patterns of failure
Table 2 shows the failure patterns for all patients. Twelve
patients in the HypoTRT group (17.4%) had locoregional
failure, 29 (42.0%) patients developed distant metastasis,
and 11(15.9%) patients exhibited both failure patterns as
first recurrence. Twenty (19.8%) of the patients who
Fig. 1 a Progression-free survival for patients in the HypoTRT and ConvTRT groups. b Overall survival for patients in the HypoTRT and ConvTRT
groups. c Locoregional recurrence probability for patients in the HypoTRT and ConvTRT groups. d Distant metastasis probability for patients in
the HypoTRT and ConvTRT groups
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received ConvTRT had locoregional failure, 35 (34.7%)
patients exhibited distant metastasis, and 13 (12.9%)
patients exhibited both failure patterns as first recurrence.
The locoregional failure included in-field failure and re-
currence outside the PTV but within the ipsilateral hilar,
bilateral mediastinal or bilateral supraclavicular nodal
basin region. The 1-year locoregional failure rates were
10.3% versus 17.6%, and the 2-year locoregional failure
rates were 34.3% versus 42.1% for the HypoTRT and
ConvTRT arms, respectively (p = 0.360) (Fig. 1c).
Distant metastasis was the main failure pattern for this
group of patients. The 1- and 2-year distant metastasis
rates were 35.2% and 54.2%, respectively, for the patients
treated with HypoTRT and were 29.4% and 52.8%,
respectively, for patients treated with ConvTRT. No
statistically significant differences in distant metastasis
were observed between groups (p = 0.804) (Fig. 1d). The
most common site of distant metastasis was the brain
(20), followed by bone (10), liver (7) and adrenal gland
(3). Brain metastases were diagnosed to the last follow-
up in 10.6% of the patients (10/94) who received PCI
and in 35.5% (27/76) of the patients who did not receive
PCI (p < 0.001). The median OS and PFS were 32.0 and
20.1 months, respectively, in patients who received PCI
compared to 23.0 and 12.3 months, respectively, in pa-
tients who did not receive PCI (p < 0.001). PCI reduced
the 2-year mortality rate from 53.9% to 30.0% and the 2-
year disease-progression rate from 79.1% to 54.7%.
Toxicity
Table 3 lists acute toxicities by site and grade. The most
common radiation-associated acute complication was
esophagitis, which was experienced by 11.6% and 9.9%
of the patients in the HypoTRT and ConvTRT arms,
respectively. One patient in the HypoTRT group and 2
patients in the ConvTRT group died of treatment-related
pneumonitis. Grade 3 to 4 leukopenia, granulocytopenia,
thrombocytopenia and anemia occurred in 55.1% and
40.6%, 52.2% and 42.6%, 28.9% and 20.8%, 10.1% and
14.8% of HypoTRT or ConvTRT patients, respectively.
No significant differences in acute toxicities were dem-
onstrated between the TRT cohorts.
Prognostic factors
Univariate analysis indicated that various potential prog-
nostic factors including gender, TNM stage, CRT modality
(concurrent vs. sequential), cycles of chemotherapy, and
PCI may influence survival. Early TRT defined as begin-
ning with 1–3 cycle of chemotherapy was not prognostic
for either PFS or OS. Multivariate analysis revealed that
PCI was prognostic factor for OS (p = 0.003, HR = 0.528,
95%CI: 0.348–0.803) and that TNM stage and PCI were
prognostic factors for PFS (p = 0.016, HR = 2.313, 95%CI:
1.169–4.578; p = 0.001, HR = 0.512, 95%CI: 0.340–0.772).
Discussion
SCLC presented high sensitivity to CRT. The integration
of TRT and etoposide/platinum chemotherapy made LS-
SCLC potentially curable [7]. A meta-analysis [5] in the
early 1990s reported that the addition of TRT to systemic
chemotherapy resulted in a 14% reduction in mortality
rate and 5.4% increase in 3-year survival. Another meta-
analysis [4] found that TRT improved 2-year survival by






Failure rates 52(75.4%) 68(67.3%) 0.259
Initial failure pattern
Locoregional failure 12(17.4%) 20(19.8%) 0.693
In field 6 9
Out of field 3 4
Both 3 7
Distant 29(42.0%) 35(34.7%) 0.330
Liver only 4 3
Bone only 5 5
Brain only 7 13
Adrenal gland only 2 1
Multiple sites 9 8




Table 3 Acute toxicities in the HypoTRT and ConvTRT groups
Acute toxicities HypoTRT group (n = 69) ConvTRT group (n = 101) P
Grade 3 4 5 3 4 5
Esophagitis 8(11.6%) 0 0 10(9.9%) 0 0 0.725
Pneumonitis 5(7.2%) 1(1.4%) 1(1.4%) 8(7.9%) 2(2.0%) 2(2.0%) 0.639
Leukopenia 30(43.5%) 8(11.6%) 0 29(28.7%) 12(11.9%) 0 0.063
Granulocytopenia 26(37.7%) 10(14.5%) 0 32(31.7%) 11(10.9%) 0 0.218
Thrombocytopenia 13(18.8%) 7(10.1%) 0 15(14.9%) 6(5.9%) 0 0.220
Anemia 6(8.7%) 1(1.4%) 0 9(8.9%) 6(5.9%) 0 0.369
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5.4% and intrathoracic tumor control by 25.3%. RT sched-
ules (Hypo-, Conv-, and HyperTRT) for LS-SCLC have
been extendedly studied over the past several decades.
Hyperfractionated-accelerated radiation of 45 Gy in
1.5 Gy twice-daily fractions with concurrent cisplatin plus
etoposide chemotherapy is a standard TRT regimen that
yielded more favorable outcomes with a median survival
of 23.0 months and 5-year OS rate of 26.0% compared to
once-daily radiation of 45 Gy (1.8 Gy per fraction) in the
INT0096 study [7]. However, this radiation regimen failed
to gain widespread acceptance because of the inconveni-
ence and high rate of severe esophagitis (32.0%) [7]. Once-
daily ConvTRT is still the most commonly used regimen
in clinical practice.
The HypoTRT is increasingly adopted in current strat-
egy to treat early and/or locally advanced NSCLC.
Nevertheless, the efficacy of HypoTRT in patients with
LS-SCLC remained unsolved. In a phase II study from
our institution, Xia et al. [15] reported a favorable me-
dian 2-year progression free survival of 49% and overall
survival of 58.2% in 59 LS-SCLC patients treated with
concurrent HypoTRT (55 Gy/22 F) and etoposide/cis-
platin. However, earlier data from Cleveland Clinic [17]
revealed that changing from a HypoTRT (40 Gy/15 F) to
a ConvTRT (50 Gy/25 F) prescription did not alter
survival or toxicity outcomes. Herein, we retrospectively
compared two radiation regimens (ConvTRT 56–66 Gy,
2.0 Gy per faction daily and HypoTRT 55 Gy, 2.5 Gy per
faction daily) combined with etoposide/platinum chemo-
therapy in 170 consecutive patients with LS-SCLC.
Even though most patient- and treatment-related vari-
ables including response rate were comparable, PCI rate
and CRT modality were not balanced between the two
cohorts. There were significantly more patients in the
HypoTRT cohort receiving early concurrent CRT and
PCI. Nevertheless, no statistically significant differences
were found between cohorts in OS or PFS. The cumula-
tive incidences of 2-year survival and PFS were 57.3% vs.
62.2% (p = 0.698) and 33.5% vs. 32.4% (p = 0.991), re-
spectively, for the ConvTRT and HypoTRT cohorts. The
survival data of HypoTRT cohort was close to those
reported by Xia et al. in the phase II trial [15]. In univar-
iate analysis, early TRT defined as beginning with 1–3
cycle of chemotherapy was not prognostic factor for
either PFS or OS. This was consistent with the systemic
review from Fried et al. [18] and the meta-analysis from
Spiro et al. [19], which suggesting that the improvement
from early TRT was small and often not evident for
once-daily fractionation.
In our study, multivariate analysis revealed that PCI was
a prognostic factor for both OS and PFS. PCI is an effective
treatment to prevent brain metastasis in LS- or ES-SCLC.
A meta-analysis in 1999 demonstrated that PCI in LS-
SCLC patients with CR resulted in an absolute decrease of
25.3% in the cumulative incidence of brain metastasis at
3 years from 58.6% to 33.3% and an absolute improvement
in survival at 3 years from 15.3% to 20.7% [20]. However,
only a portion of patients with response received PCI in
clinical practice. Patel et al. [21] reported that PCI was only
delivered in 8% patients by reviewing LS-SCLC data
between 1988 and 1997 in the SEER program and that the
5-year survival rate was 19% in patients who received PCI
compared to 11% in patients who did not receive PCI
(p < 0.01). PCI was administered in 55% of the LS-
SCLC patients in our study. PCI improved the 2-year
survival rate from 46.1% to 70.0% and the 2-year PFS
rate from 20.9% to 45.3%, respectively (p < 0.001). In
this group of patients, PCI reduced brain metastasis
rate from 35.5% (27/76) to 10.6% (10/94), and was corre-
lated with improved PFS and OS, highlighting the import-
ance of PCI for those responders. Nevertheless, this
finding should be interpreted with caution, because a
higher proportion of patients receiving PCI were treated
with concurrent CRT and more cycles of chemotherapy.
The effect of multiple testing cannot be ruled out.
The once-daily HypoTRT regimen became more prac-
ticable in recent years because of improved normal
tissue protection via 3DCRT and IMRT. A shortened
duration of the HypoTRT regimen may decrease cancer
cell repopulation [13]. Locoregional recurrence in the
present study occurred in 32.9% of patients, and there
was no difference between the HypoTRT (33.3%) and
ConvTRT (32.7%) cohorts. Distant failure often precedes
locoregional recurrence and presents as the primary pat-
tern of failure because of the early dissemination behavior
of SCLC. In our report, 120 (70.6%) patients experienced
disease progression, which was most frequently distant
metastasis (51.8%). Forty patients (58.0%) in the HypoTRT
group and 48 (47.5%) patients in the ConvTRT group with
or without locoregional recurrence experienced initial
distant metastasis at the last follow-up.
Few significant acute toxicities were observed in the
current study. The most common Grade 3 or worse acute
toxicity was myelosuppression. A total of 11.6% and 11.9%
of patients in the HypoTRT and ConvTRT group, respect-
ively, experienced grade 4 leukopenia. The main radiation-
associated toxicities were esophagitis and pneumonitis.
Severe esophagitis was reported in 9.9% of patients in the
ConvTRT cohort and 11.6% of patients in the HypoTRT
cohort in our study. The rate of pneumonitis was 11.9% in
the ConvTRT arm and 10.0% in the HypoTRT arm.
Watkins et al. [22] reported that severe esophagitis and
pneumonitis with once-daily TRT occurred in 24.0% and
6.0% of patients, respectively, compared with 20.0% and
4.0% in the twice-daily group, and one patient treated with
twice-daily TRT died of treatment-associated pneumonitis.
However, in a recent phase III trial [23], grade 3–4 esopha-
gitis was 0.9%–3.6% for Korean patients who received
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concurrent CRT. Overall, the toxicities in our study
seemed tolerable and acceptable. Notably, all patients en-
rolled in our study received 3D-CRT or IMRT treatment
on the basis of involved-field radiotherapy.
There are certain limitations of our study. It was retro-
spective and the sample size was not large enough. The
PCI rate and timing of TRT were not balanced between
the two arms of patients who received Conv- or HypoTRT.
A higher proportion of patients received early TRT and
PCI in the HypoTRT arm. The selection bias may affect
the results of the statistical analysis.
Conclusions
This retrospective analysis demonstrated that HypoTRT
or ConvTRT combined with etoposide/platinum chemo-
therapy yielded statistically similar survival, treatment
failure outcomes, and toxicity profiles. PCI correlated
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